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Abstract
Background: The Children’s Oncology Group (COG) is the only organization within the National Cancer Institute’s
National Clinical Trials Network dedicated exclusively to pediatric cancer research. The purpose of this article is to
provide an overview of COG’s organizational structure, to characterize its institutional and individual membership,
and to summarize enrollments onto COG clinical trials. Method: Data from 2013 to 2015 were compiled from
sources internal (Network Operations, Statistics and Data Center, Chair’s Office) and external (American Hospital
Association, American Nurses Credentialing Center) to COG, to present a comprehensive overview of COG’s
structure, individual and institutional membership, and group operations. Results: In 2016, COG comprised 8,785
individuals from 223 member institutions, across seven countries. An average of 9,661 new patients were registered
with COG per year over the most recent (2013-2015) 3-year period. Over the same 3-year time frame, there
were an average of 16,836 enrollments onto therapeutic (i.e., treatment) and nontherapeutic (e.g., epidemiology,
survivorship, biology) trials per year. Conclusions: COG institutions have diverse characteristics related to size,
geographical location, and infrastructure. Individual membership also reflects diversity with representation from over
28 disciplines and groups. The diversity of COG institutions and individual members allows for unique perspectives
and contributions to science unified under a common goal to enroll children/adolescents onto clinical trials. COG’s
collaborative, multidisciplinary approach to science functions to support the development of research that seeks to
continually improve outcomes for children and adolescents with cancer.
Keywords
clinical trials, pediatric oncology, cooperative group, research

Introduction
The foundation for oncology clinical trials groups in the
United States began in 1955, when funding was appropriated by Congress to the National Cancer Institute (NCI)
in order to establish the Cancer Chemotherapy National
Service Center (Mauer, Rich, & Schilsky, 2007). This set
in motion collaborations between institutions to evaluate
potential anticancer agents. First among these collaborations was Leukemia Group A—the vanguard of the legacy pediatric oncology clinical trials groups. Over the
ensuing five decades, additional clinical trials groups
were established with the overarching purpose of conducting multi-institutional trials to improve cancer outcomes, and a Cooperative Group Program to fund and
support the infrastructure for oncology clinical trials was
firmly established by the NCI. Four of the legacy groups
founded during this era (the Children’s Cancer Group, the

Intergroup Rhabdomyosarcoma Study Group, the
National Wilms Tumor Study Group, and the Pediatric
Oncology Group) maintained a pediatric oncology focus,
and voluntarily merged in the year 2000 to form the
Children’s Oncology Group (COG; O’Leary, Krailo,
Anderson, & Reaman, 2008). The COG thus became the
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sole pediatric-focused clinical trials program among the
10-member NCI Cooperative Group Program.
Subsequent recommendations from the Institute of
Medicine (Nass, Moses, & Mendelsohn, 2010) regarding
the need for a more efficient, responsive, and collaborative clinical trials system led the NCI to restructure and
transform the Cooperative Group system into the National
Clinical Trials Network (NCTN), which was launched in
March 2014. This change reduced the number of groups
that receive NCI clinical trial funding support from 10 to
5, with four U.S.-based groups designated for adultfocused trials: (1) Alliance (Alliance for Clinical Trials in
Oncology, formed by the merger of the American College
of Surgeons Oncology Group, Cancer and Leukemia
Group B, and North Central Cancer Treatment Group),
(2) ECOG-ACRIN Cancer Research Group (Eastern
Cooperative Oncology Group and the American College
of Radiology Imaging Network), (3) NRG Oncology
(formed through the merger of the National Surgical
Adjuvant Breast and Bowel Project, the Radiation
Therapy Oncology Group, and the Gynecologic Oncology
Group), and (4) SWOG (formerly known as the Southwest
Oncology Group)—and one group for pediatric-focused
clinical trials: COG (U.S. Department of Health and
Human Services, 2015). This massive change in infrastructure was implemented to reduce duplication of effort
across groups and to position the funded groups to work
together in order to maximize the potential for scientific
progress in the era of precision medicine (U.S. Department
of Health and Human Services, 2015).
Today, COG is the world’s largest research organization dedicated exclusively to children and adolescents
with cancer. In the United States, an estimated 10,270
children ages 0 to 14 years will be diagnosed with cancer
in 2017 (Siegel, Miller, & Jemal, 2017), and over 90% of
these children will be treated at COG member institutions
(O’Leary et al., 2008). An additional 5,000 adolescents
annually (ages 15-19 years) will be diagnosed with cancer in the United States (American Cancer Society, 2017).
Since its formation, COG has operated with the mission to cure and prevent childhood and adolescent cancer
through scientific discovery and compassionate care
(COG, 2000). As COG has matured, its structure and
membership have evolved. The purpose of this article is
to provide an overview of COG’s current organizational
structure and to characterize its membership, institutions
and clinical trial enrollments.

Network Operations Center. Patient registration and clinical trial enrollment data (i.e., annual COG registrations and
enrollments per institution, and therapeutic and nontherapeutic trial enrollments by disease type) were obtained from
the Statistics and Data Center (SDC). Registrations were
reported as the average number of unique patients registered with COG per institution per year over a 3-year rolling
average (2013, 2014, 2015), while enrollments were
reported as the average number of patients enrolled on therapeutic and nontherapeutic trials (excluding studies solely
funded by industry) per institution per year over the same
3-year time period; all data were frozen as of December 12,
2015. Data related to COG’s organizational structure, membership criteria, and leadership were obtained from the
Group Chair’s Office. Detailed institutional characteristics
of member institutions (i.e., number of inpatient beds,
teaching hospital status, hospital type, and funding structure) were abstracted from the American Hospital
Association Guide (American Hospital Association, 2015)
for institutions within the United States, and from publically available websites, when available, for institutions
outside the United States. Institutions were categorized as
teaching hospitals if they met one of the following criteria
reported by the American Hospital Association Guide
(American Hospital Association, 2015): approval through
the Accreditation Council for Graduate Medical Education
to participate in residency training; Medical School
Affiliation, reported to the American Medical Association,
or a Member of the Council of Teaching Hospitals of the
Association of American Medical Colleges. Data regarding
institutional characteristics were internally verified with
COG members who were knowledgeable regarding member site affiliations and characteristics. The American
Nurses Credentialing Center (ANCC) website was used to
determine which COG institutions hold ANCC Magnet
designation, a widely recognized indicator of quality nursing care (Morgan, Lahman, & Hagstrom, 2006). Additional
institutional data (e.g., type of unit where pediatric oncology patients are treated, and proportion of non–Englishspeaking families) were collected as part of a comprehensive
survey of COG member institutions conducted in 20142015 (response rate >90%), the methodology of which has
been previously published (Withycombe et al., 2016).

Method

COG comprises multiple individuals and committees that
provide leadership and function collectively to operationalize the mission of the organization (Figure 1). Five guiding
principles form the foundation for the work of the organization: (1) integrating the best science (2) assuring the highest
ethical standards for research conduct; (3) transforming

Data related to COG member institutions (i.e., geographic
location, dates of membership, number of individual members, consortium participation), and aggregate individual
membership data by discipline, were obtained from the

Results
Organizational Structure
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Figure 1. Children’s Oncology Group organizational structure.

outcomes through expert, multidisciplinary collaboration;
(4) engaging the entire research community (children, families, patient advocates, frontline investigators, NCI, and
industry partners) in participating in the development and
conduct of research; and (5) recognizing responsibility to
patients, families, science, and funding organizations.

Funding
As the sole pediatric clinical trials group operating within
the NCTN, COG is primarily supported through NCI
funding that includes primary grants for the Network
Operations Center, the SDC, and the Biopathology
Center. Additional network grants support the Phase 1/
Pilot Consortium as well as the NCI Community
Oncology Research Program.

Leadership
COG’s leadership structure encompasses three branches,
which include the Group Chair, the Executive Committee,
and the Voting Body. The Constitution and Bylaws, which
guide the governance of the organization, were enacted in
2000 and are reassessed at least every 5 years. The Group
Chair is an elected individual who serves as the organization’s chief executive officer for a term of 5 years, renewable once. The Group Chair has responsibility for the
overall administrative, fiscal, and scientific leadership of
COG. This includes serving as principal investigator (PI)
of the NCTN Group Operations Grant and other appropriate grants, leading the Executive Committee, appointing
individuals to scientific leadership positions, overseeing

the Network Operations Center, and representing COG at
the NCI. The Group Statistician is appointed by the Group
Chair (with approval of the Executive Committee) to
oversee the SDC, to serve as PI for the SDC grant, and to
provide statistical direction to the Scientific Council. The
Executive Committee is composed of the Group Chair and
18 additional voting members, including the vice chair,
the Group Statistician, and representatives of the member
institutions and the scientific and administrative committees. The Executive Committee is responsible for strategic
planning of the organization and oversees fiscal, administrative, and legal issues. The Voting Body comprises PIs
from each member institution and cofunctions with the
Group Chair and the Executive Committee to provide
guidance for ensuring execution of COG’s mission. The
Voting Body is also responsible for electing the Group
Chair, approving new member institutions, and ratifying
amendments to the organizational constitution. The
Scientific Council, whose members are appointed by the
Group Chair, provides guidance regarding the scientific
direction of COG research, reviews scientific concepts,
prioritizes research efforts, and assures conduct of research
to the highest scientific standards.

Committees
Research proposals that support the overall COG mission
arise from Disease, Discipline, and Domain Committees.
These Committees serve to develop and vet research concepts and priorities, which are then submitted to the
Scientific Council for consideration of further development. Table 1 details the array of the COG committees.
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Table 1. COG Committees.
Administrative Committees

Discipline Committees

Disease Committees
• Acute Lymphoblastic
Leukemia
• Acute Myeloid
Leukemia
• Bone Tumors

•

Bioethics

•

Adolescent-Young Adult

•

Data and Safety Monitoring

•

Behavioral Science

• Diversity and Health
Disparities
• Executive

•

Clinical Research Associates

•

Cytogenetics

• Industry Relations Advisory
• Institutional Performance
Monitoring
• International Affairs

•
•

Diagnostic Imaging
Hematology/Oncology

•

Membership

•
•
•
•
•
•
•
•

NCORP
Nominating
Patient Advocacy
Return of Results
Scientific Chairs
Scientific Council
Voting Body
Young Investigators

• Integrated Translational
Science (Hematologic
Malignancies)
• Integrated Translational
Science (Solid Tumors)
• Laboratory Science
• Neuroscience
• Nursing
• Pathology
• Pharmacy
• Radiation Oncology
• Statistics
• Surgery

• Central Nervous
System Tumors
• Hodgkin Disease
• Neuroblastoma

Domain Committees
• Cancer Control/
Supportive Care
• Cellular Therapy
• Developmental
Therapeutics
• Epidemiology
•

Outcomes-Survivorship

• Non-Hodgkin
Lymphoma
•

Rare Tumors

•
•

Renal Tumors
Soft Tissue Sarcomas

Note. COG = Children’s Oncology Group; NCORP = National Cancer Institute Community Oncology Research Program.

The Disease Committees are multidisciplinary teams
that develop and implement top research priorities for
their specific disease areas by designing clinical trials.
Discipline Committees include members of a single
discipline (e.g., Hematology/Oncology, Nursing, and
Pharmacy) or members that share a particular area of
expertise (e.g., Adolescent-Young Adult Oncology).
Domain Committees (e.g., Outcomes-Survivorship)
develop research concepts that bridge important topics
across disease groups and/or disciplines. Some Discipline
and Domain Committees have secured external funding
to facilitate conduct of their studies within COG.
Administrative Committees (e.g., Membership, Data,
and Safety Monitoring) serve to ensure compliance with
safety, membership, and regulatory requirements. The
Patient Advocacy Committee is another Administrative
Committee, which serves to provide the patient/family
perspective on research-related processes as well as
feedback regarding the development of educational
materials. Finally, specialty consortia are groups of institutions that work with COG to carry out research pertaining to a specific focus area. For example, the Phase 1/
Pilot Consortium is aligned with the COG Developmental
Therapeutics Domain Committee in order to identify and
develop new agents for use in pediatric oncology.

Core Resources
Core Resources within the COG include (1) the Network
Operations Center and Group Chair’s Office, (2) the
SDC, (3) the Biopathology Center, (4) the Information
Technology Core, and (5) the Quality Assurance and
Audit Department. The Network Operations Center and
the Chair’s Office are governed by the Group Chair and
are responsible for endeavors such as protocol development, processing membership applications, preparation
and management of grants, development and maintenance of policies and procedures, meeting planning, and
managing collaborations with industry and other research
sponsors. The SDC serves to provide statistical support
related to protocol development, data analysis, and collaboration for abstract and manuscript development. The
SDC is also responsible for overseeing patient registration, enrollment, and data collection as well as generating
reports related to study progress, patient safety, and
interim outcome analyses. The Biopathology Center is
directly responsible for managing pathological and biological specimens that support COG research. This
includes the provision of a central repository for pathologic materials (procurement, banking, and distribution),
a uniform approach to the diagnosis of pediatric tumors,
and confirmation of diagnosis for select protocols. The
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Information Technology Core ensures maintenance of a
secure, regulatory-compliant informatics environment,
including a member website, application development,
and integrations with NCI systems, to facilitate the work
of COG. The Quality Assurance and Audit Department is
responsible for assuring adherence with all regulatory
requirements related to the protection of human subjects,
and assurance of protocol compliance. This department
conducts on-site audits for all member institutions in full
accordance with regulatory entities (including but not
limited to the NCI, the Clinical Trials Monitoring Branch,
and the Food and Drug Administration). The Quality
Assurance and Audit Department also works with the
Institutional Performance Monitoring Committee to identify and resolve issues related to the conduct of COG trials. Although external to COG, the Pediatric Central
Institutional Review Board (IRB; NCI, n.d.) was established in 2004 through the NCI to provide core regulatory
support by partnering with local institutions to conduct
IRB reviews of selected NCI-sponsored pediatric trials.
This initiative was implemented to help reduce the
administrative burden on local IRBs in relationship to
opening multiple COG trials.

Membership Characteristics
Children’s Oncology Group membership occurs on two
levels: individual and institutional.
Individual Membership. Individuals may submit an application for membership if they are affiliated with a COG institution or support unit (e.g., the Operations Center), are
activity engaged in the care of children with cancer or
assist with other support activities, and meet the membership criteria for a specific discipline. Individual applications must receive approval from the Membership
Committee and the Group Chair. In 2016, there were 8,785
individual COG members. Individual membership is multidisciplinary (Figure 2) consisting of pediatric oncologists
(21%), pediatric oncology nurses (27%), clinical research
associates (12%), pharmacists (11%), surgeons (5%), fellows/other guest members (5%), pathologists (4%), radiation oncologists (4%), behavioral scientists (2%), and other
professionals (9%) including representatives from cytogenetics, neuroscience, statistics, administration, bioethics,
cardiology, endocrinology, information technology, consultants, other medical practitioners, nutrition, patient
advocacy, laboratory science, and epidemiology.
Nursing represents one of the largest disciplines
within COG and is actively engaged in many aspects of
clinical trial development and implementation. Nursing
activities include clinical trial involvement (e.g., serving
as nursing representatives on Clinical Trials or Disease
Committees), nursing research (e.g., developing and
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Figure 2. Individual Children’s Oncology Group membership
by discipline (as of December 31, 2015; N = 8,785).

implementing nurse-led research studies), evidencebased practice projects (e.g., conducting systematic
reviews and developing evidence-based summaries to
guide clinical trials–related pediatric oncology nursing
practice), and education (e.g., development of the COG
Family Handbook and creation and presentation of clinical trial–related educational programs for nurses).
Institutional Membership. Institutional membership requires
submission of an application from a medical center, independent hospital, or research institute that meets the requirements for pediatric cancer centers as established by COG.
Each member institution must have a pediatric oncologist
committed to serving as PI for COG studies and other related
activities, as well as multidisciplinary members who meet
discipline-specific membership requirements. All member
institutions must be committed to enrolling patients on COG
clinical trials and must continue to meet membership criteria
pertaining to competence, required enrollment numbers,
performance, and compliance on an ongoing basis, as outlined in COG’s constitution and bylaws.
As of 2016, COG institutional membership (Table 2)
includes 223 institutions located in 7 countries. While 87%
of institutions are located within the United States, additional member sites are located in Canada, Australia, Ireland,
New Zealand, Saudi Arabia, and Switzerland. Within the
United States, the state of California has the largest number
of COG member institutions (n = 19), while all other U.S.
states are represented by at least one member institution,
with the exception of Kansas, Montana, and Wyoming.
Overall, 21 institutions participate in the COG Phase 1
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Table 2. Characteristics of COG Member Institutions
(N = 223).
Characteristic

N

Table 2. (continued)
Characteristic
%

Geographic location
  United States
194
87.0
  Canada
15
6.7
  Australia
8
3.6
  Other
6
2.7
COG annual registrations per institution (3-year rolling
average)a
  <20
62
27.8
  20-50
102
45.7
  >50
59
26.5
  M (SD)
43.3
40.1
  Mdn (range)
31 3-339
COG annual enrollments per institution (3-year rolling
average)a
  <20
20
9.0
  20-50
83
37.2
  >50
120
53.8
  M (SD)
75.5
65.6
  Mdn (range)
56 1-364
Length of COG institutional membership, years
  >15 (prior to pediatric cooperative
187
83.8
group merger)
  6-15
18
8.1
  1-5
18
8.1
Average no. of individual COG members per institution
  M (SD)
39.8
33.8
  Mdn (range)
30 9-193
COG consortium participation
   COG Phase 1 consortium site
21
9.4
  NCORP site
38
17.0
   COG Stem Cell Transplant Center
88
39.5
Hospital structure (n = 218)b
   Freestanding children’s hospital
63
28.9
   Children’s hospital within adult medical
114
52.3
center
   Other (e.g., community hospital)
41
18.8
No. of inpatient beds (n = 206)b
  <100
5
2.4
  100-400
76
36.9
  401-700
75
36.4
  >700
50
24.3
Hospital unit type (caring for newly diagnosed oncology
patients; n = 201)b
  General pediatric
88
43.8
   Specialized pediatric oncology
113
56.2
Educational affiliation (n = 194)b
  Teaching hospital
185
95.4
  Nonteaching hospital
9
4.6
ANCC magnet accreditation (n = 218)b
  Yes
76
34.9
  No
142
65.1
(continued)

N

%

b

Institutional financial structure (n = 214)
  Nonprofit
145
67.8
  Government-owned
59
27.5
  For-profit
10
4.7
Proportion of non– or limited–English-speaking families at
institution (n = 194)b
⩾25%
66
34.0
<25%
128
66.0
Note. COG = Children’s Oncology Group; NCI = National Cancer
Institute; NCORP = National Cancer Institute Community Oncology
Research Program; ANCC = American Nurses Credentialing Center.
Table partially adapted and updated from Withycombe et al. (2016).
a
Years 2013-2015. bData available only for the number of institutions
indicated.

Consortium, while 88 institutions are designated as stem cell
transplant centers. Within the United States, 38 sites are NCI
Community Oncology Research Program participants, with
14 of these categorized as serving underserved/minority
populations. The average (M ± SD) number of individual
members per institution is 39.8 ± 33.8; (Mdn = 30; range =
9-193). The large majority of institutions (84%) were members of the NCI’s Cooperative Group Program prior to the
merger of the four pediatric legacy groups that formed COG
over 16 years ago; 36 additional institutions secured membership following the merger.
Twenty-nine percent of COG institutions are freestanding children’s hospitals, while 52% are organizationally aligned with adult hospitals (i.e., children’s
hospitals within larger adult medical centers), and the
remaining 19% of sites comprise other hospital types
(e.g., community hospitals, freestanding cancer centers).
Newly diagnosed pediatric oncology patients are cared
for on specialized pediatric oncology units at 56% of
member institutions, and on general pediatric wards at the
remaining 44% of sites. Thirty-four percent of institutions reported that at least 25% of families at their sites
were limited- or non–English-speaking. The majority
(68%) of institutions reported a not-for-profit funding
structure, and 95% (of U.S. institutions) function as
teaching hospitals. In addition, 36% of U.S. institutions
have 100 to 400 inpatient beds, 36% have 401 to 700 and
25% have ⩾701 beds. Thirty-five percent of COG sites
have achieved ANCC Magnet® accreditation.

Research Portfolio Characteristics
The key to achieving COG’s mission hinges on the ability
to consistently develop and open effective research studies
and to successfully meet accrual goals for these studies in
a timely manner. COG maintains a diverse research portfolio that includes therapeutic trials spanning the spectrum of
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Table 3. Open Therapeutic Trials by Year.
Phase
Phase 2
Phase 3

2013

2014

2015

14
21

12
20

14
17

Note. Number of trials with active enrollment/year.

pediatric cancer diagnoses, including acute lymphoblastic
leukemia (Hunger et al., 2013), acute myeloid leukemia
(Gamis et al., 2013), Hodgkin (Kelly et al., 2013) and nonHodgkin lymphoma (Bollard, Lim, Gross, & COG NonHodgkin Lymphoma Committee, 2013), central nervous
system tumors (Gajjar et al., 2013), bone tumors (Gorlick
et al., 2013), soft tissue sarcomas (Hawkins Spunt, Skapek,
& COG Soft Tissue Sarcomas Committee, 2013), renal
tumors (Dome et al., 2013), neuroblastoma (Park et al.,
2013), and rare tumors (Rodriguez-Galindo et al., 2013).
These studies are designed to address important gaps in
scientific knowledge and advance the field of pediatric
oncology (Adamson, 2013).
During 2013 to 2015, there were 40 Phase 2 and 58
Phase 3 trials open with active patient enrollment (Table 3).
COG maintains a strong developmental therapeutics program that includes a Phase 1 consortium and industry collaborations. A variety of nontherapeutic studies are also
ongoing, including correlative/biology (Adamson, 2013),
cancer control (Sung et al., 2013), epidemiology (Spector,
Ross, Olshan, & COG Epidemiology Committee, 2013),
and survivorship/long-term follow-up (Armenian et al.,
2013) studies. The diverse portfolio of research often provides opportunities for patients to participate in more than
one study during the course of treatment and follow-up.
Across COG, an average of 9,661 new patients were
registered per year over the most recent (2013-2015)
3-year period (M ± SD registrations per institution = 43.3
± 40.1; Mdn = 31; range = 3-339]). Over the same 3-year
timeframe, there were an average of 16,836 enrollments
onto therapeutic (i.e., treatment) and nontherapeutic (e.g.,
epidemiology, survivorship, biology) trials per year (M ±
SD enrollments per institution = 75.5 ± 65.6; Mdn = 56;
range = 1-364). Annual enrollments averaged <20
patients at 9% of sites; 20 to 50 patients at 37% of sites;
and >50 patients at 54% of sites. During 2013 to 2015,
there were a total of 11,335 enrollments onto therapeutic
clinical trials (across all disease types; Figure 3), including 8,532 enrollments onto leukemia trials, 905 enrollments onto neuroblastoma trials, 661 enrollments onto
trials for central nervous system tumors, 609 enrollments
onto bone and soft tissue sarcoma trials, 339 enrollments
onto lymphoma trials, 186 enrollments onto trials for renal
tumors, and 58 enrollments onto trials for rare tumors.
During 2013 to 2015, there were also 38,350 enrollments
onto nontherapeutic trials (Figure 4), including 14,248

enrollments onto biology trials (Figure 5). Importantly, all
institutions made substantial contributions to study enrollments, regardless of size; with almost half (47.2%) of
study enrollments contributed by institutions enrolling
100 or fewer patients per year (Figure 6). Enrollments
from smaller and midsized institutions often represent
diverse and underserved populations, such as Native
Americans and those from rural areas.

Discussion
To our knowledge, this article is the first to provide an
overview of COG’s organizational structure and to
describe the characteristics of its individual and institutional membership. While we found wide variability in
institutional characteristics across COG, this was not
unexpected; in fact, this variability may be viewed as an
organizational strength. The diverse geographic locations
of the member institutions ensure that participation in
contemporary COG clinical trials is an option for almost
all children diagnosed with cancer within the United
States. This aligns with NCTN’s goal to increase accessibility of clinical trials for potential participants (U.S.
Department of Health and Human Services, 2015) and
enhances the probability that a large proportion of eligible children will be enrolled onto COG clinical trials.
Despite the variability in institutional characteristics,
such as size, hospital type, and geographic location, COG
institutional membership facilitates the standardization of
treatment for pediatric cancers by enrollment of children
onto treatment protocols across settings. This strengthens
COG’s ability to rapidly address important questions and
improve outcomes for children with cancer. Additionally,
because of the wide range of institutions participating in
COG, children representative of the broader characteristics of the population can be adequately recruited for
study enrollment, enhancing generalizability of study
findings. Over one third of COG institutions reported that
at least 25% of families at their sites were limited– or
non–English-speaking. This speaks to the diversity of
COG’s patient population. COG has committed efforts
toward providing supportive literature for patients and
families in multiple languages, which serves as an example of the efforts required to ensure that vulnerable subgroups of patients are not marginalized. For example, the
COG Family Handbook (Murphy, 2011) is available in
English, Spanish, and French. Continued awareness and
attention to the needs of non–English-speaking patients
and their families are warranted.
With regard to COG’s individual membership (Figure 2),
variability also exists related to the multidisciplinary nature
of the organization and representation from diverse groups
(e.g., hematologists/oncologists, nurses, pharmacists, laboratory scientists, and others such as patient advocates). This
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Figure 3. COG enrollments, 2013-2015: Enrollments to COG therapeutic trials (N = 11,335).a

Note. COG = Children’s Oncology Group; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; Bone = Ewing sarcoma and
osteosarcoma; CNS = central nervous system; NBL = neuroblastoma; NHL = non-Hodgkin lymphoma; Rare = germ cell tumors, liver tumors,
and retinoblastoma; STS = soft tissue sarcoma; Other = stem cell transplant and developmental therapeutics.
a
Enrollment on multiple trials allowed for eligible subjects.

Figure 4. COG enrollments, 2013-2015: Enrollments to COG Nontherapeutic trials (N = 38,350).a

Note. COG = Children’s Oncology Group; Admin = administrative; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia;
Bone = Ewing sarcoma and osteosarcoma; CCL = cancer control; CNS = central nervous system; LE = late effects; NBL = neuroblastoma;
NHL = non-Hodgkin lymphoma; STS = soft tissue sarcoma; Other = epidemiology, nursing, and biopathology and translational research.
a
Enrollment on multiple trials allowed for eligible subjects.

provides an environment rich for networking and sharing
expertise across disciplines. Multidisciplinary involvement
of the membership through appointments to Disease and
Domain Committees helps ensure thoughtful attention to all
aspects of planned studies.
The primary limitation of this article is that the institutional data obtained from the American Hospital
Association (2015) Guide is reported at an aggregate
level. Therefore, certain data (e.g., number of beds) may
have been reported for the entire organization and may

not be a true representation of the characteristics of pediatric facilities that are located within larger medical centers. To more accurately reflect the size and volume of the
pediatric oncology programs at each member institution,
we reported COG enrollment and registration data.
Additionally, the institutional survey data were reported
by a single individual at each COG site, and it is possible
that this information could be biased or inaccurate; however, this possibility was controlled for by using a stringent recruitment method that required experienced and

32

Journal of Pediatric Oncology Nursing 36(1)

Figure 5. COG enrollments, 2013-2015: Enrollments to COG biology trials (N = 14,248).a

Note. COG = Children’s Oncology Group; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; Bone = Ewing sarcoma and
osteosarcoma; BTR = biopathology and translational research; CNS = central nervous system; NBL = neuroblastoma; NHL = non-Hodgkin
lymphoma; STS = soft tissue sarcoma.
a
Enrollment on multiple trials allowed for eligible subjects.

Figure 6. COG enrollments, 2013-2015: Annual COG study enrollments categorized by average enrollments per institution.
Note. COG = Children’s Oncology Group. The average number of annual enrollments per institution are shown on the x-axis and the total
annual enrollments contributed by sites are shown on the y-axis.

knowledgeable individuals to represent each institution.
Despite these limitations, this study has numerous
strengths, including the use of data from multiple sources,
as well as data provided directly from the COG Network
Operations Center and SDC.
Our findings suggest that there is variability in the
characteristics of COG institutions, with regard to infrastructure (e.g., hospital type), size (number of inpatient
beds, annual COG registrations and enrollments), and
other characteristics (e.g., number of individual members,
Phase 1 or Stem Cell Transplant sites, proportion of non–
or limited–English-speaking families). Characteristics of

the 8,785 individual members of COG are also diverse,
with representation from over 28 unique disciplines and/
or groups. This extensive diversity within COG represents
a significant strength, as it brings substantial expertise and
unique perspectives to the development and conduct of
clinical trials aimed at improving outcomes in children
and adolescents with cancer.
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